Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Investigational drugs in recent clinical trials for treatment-resistant depression.

Garay RP, Zarate CA Jr, Charpeaud T, Citrome L, Correll CU, Hameg A, Llorca PM.

Expert Rev Neurother. 2017 Jun;17(6):593-609. doi: 10.1080/14737175.2017.1283217. Epub 2017 Jan 29. Review.

2.

Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries.

Garay RP, Citrome L, Samalin L, Liu CC, Thomsen MS, Correll CU, Hameg A, Llorca PM.

Expert Opin Pharmacother. 2016;17(7):921-36. doi: 10.1517/14656566.2016.1149164. Epub 2016 Feb 19. Review.

PMID:
26831200
3.

Potential serotonergic agents for the treatment of schizophrenia.

Garay RP, Bourin M, de Paillette E, Samalin L, Hameg A, Llorca PM.

Expert Opin Investig Drugs. 2016;25(2):159-70. doi: 10.1517/13543784.2016.1121995. Epub 2015 Dec 15. Review.

PMID:
26576669
4.

Investigational drugs for anxiety in patients with schizophrenia.

Garay RP, Samalin L, Hameg A, Llorca PM.

Expert Opin Investig Drugs. 2015 Apr;24(4):507-17. doi: 10.1517/13543784.2014.987339. Epub 2014 Nov 25. Review.

PMID:
25423603
5.

Bipolar disorder: recent clinical trials and emerging therapies for depressive episodes and maintenance treatment.

Garay RP, Llorca PM, Young AH, Hameg A, Samalin L.

Drug Discov Today. 2014 Nov;19(11):1792-1800. doi: 10.1016/j.drudis.2014.07.010. Epub 2014 Jul 24. Review.

PMID:
25066425
6.

Polytetrafluoroethylene-covered nitinol stent graft for treatment of carotid artery blowout syndrome in head and neck cancer patients.

Hakime A, Khoury E, Hameg A, Liberge R, Deschamps F, Farouil G, Joskin J, Tselikas L, Temam S, Janot F, De Baere T.

Laryngoscope. 2013 Jul;123(7):1670-5. doi: 10.1002/lary.24006. Epub 2013 Mar 11.

PMID:
23483533
7.

Unsuspected hibernating myocardium detected by routine oncology (18)F-FDG PET/CT.

Vilain D, Bochet J, Le Stanc E, Wattel C, Hameg A, Tainturier C.

Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):409. doi: 10.1007/s00259-009-1323-6. Epub 2009 Dec 9. No abstract available.

PMID:
19997913
8.

Psychopathological correlates of lifetime anxiety comorbidity in bipolar I patients: findings from a French national cohort.

Azorin JM, Kaladjian A, Adida M, Hantouche EG, Hameg A, Lancrenon S, Akiskal HS.

Psychopathology. 2009;42(6):380-6. doi: 10.1159/000241193. Epub 2009 Sep 24.

PMID:
19776668
9.

Risk factors associated with lifetime suicide attempts in bipolar I patients: findings from a French National Cohort.

Azorin JM, Kaladjian A, Adida M, Hantouche E, Hameg A, Lancrenon S, Akiskal HS.

Compr Psychiatry. 2009 Mar-Apr;50(2):115-20. doi: 10.1016/j.comppsych.2008.07.004. Epub 2008 Sep 20.

PMID:
19216887
10.

FDG PET/CT findings in secondary hyperparathyroidism not mimicking multiple bone metastases.

Le Stanc E, Wattel C, Hameg A, Vilain D, Tainturier C, Theodore C.

Eur J Nucl Med Mol Imaging. 2009 Feb;36(2):334. doi: 10.1007/s00259-008-1015-7. Epub 2008 Dec 18. No abstract available.

PMID:
19093109
11.

[A review of bone scintigraphy in metastases from urological malignancies in adults].

Vilain D, Hameg A, Tainturier C.

Prog Urol. 2008 Nov;18 Suppl 7:S202-7. doi: 10.1016/S1166-7087(08)74543-3. French.

PMID:
19070792
12.

Cyamemazine metabolites: effects on human cardiac ion channels in-vitro and on the QTc interval in guinea pigs.

Crumb W, Benyamina A, Arbus C, Thomas GP, Garay RP, Hameg A.

J Pharm Pharmacol. 2008 Nov;60(11):1507-13. doi: 10.1211/jpp/60.11.0012.

PMID:
18957172
13.

Factors associated with rapid cycling in bipolar I manic patients: findings from a French national study.

Azorin JM, Kaladjian A, Adida M, Hantouche EG, Hameg A, Lancrenon S, Akiskal HS.

CNS Spectr. 2008 Sep;13(9):780-7.

PMID:
18849897
14.

Toward the delineation of mania subtypes in the French National EPIMAN-II Mille Cohort. Comparisons with prior cluster analytic investigations.

Azorin JM, Kaladjian A, Adida M, Hantouche E, Hameg A, Lancrenon S, Akiskal HS.

Eur Arch Psychiatry Clin Neurosci. 2008 Dec;258(8):497-504. doi: 10.1007/s00406-008-0823-x. Epub 2008 Jun 20.

PMID:
18574610
15.

Two-year study of relapse prevention by a new education program in schizophrenic patients treated with the same antipsychotic drug.

Chabannes JP, Bazin N, Leguay D, Nuss P, Peretti CS, Tatu P, Hameg A, Garay RP, Ferreri M.

Eur Psychiatry. 2008 Jan;23(1):8-13. Epub 2007 Oct 26.

PMID:
17964764
16.

Characterization of human cytochrome P450 enzymes involved in the metabolism of cyamemazine.

Arbus C, Benyamina A, Llorca PM, Baylé F, Bromet N, Massiere F, Garay RP, Hameg A.

Eur J Pharm Sci. 2007 Dec;32(4-5):357-66. Epub 2007 Sep 14.

PMID:
17951033
17.

Affinity of cyamemazine metabolites for serotonin, histamine and dopamine receptor subtypes.

Benyamina A, Arbus C, Nuss P, Garay RP, Neliat G, Hameg A.

Eur J Pharmacol. 2008 Jan 14;578(2-3):142-7. Epub 2007 Oct 2.

PMID:
17936750
18.

Effects of cyamemazine on hERG, INa, ICa, Ito, Isus and IK1 channel currents, and on the QTc interval in guinea pigs.

Crumb W, Llorca PM, Lancon C, Thomas GP, Garay RP, Hameg A.

Eur J Pharmacol. 2006 Feb 27;532(3):270-8. Epub 2006 Feb 21.

PMID:
16494862
19.

Neuroprotective effect of riluzole in acute noise-induced hearing loss.

Ruel J, Wang J, Pujol R, Hameg A, Dib M, Puel JL.

Neuroreport. 2005 Jul 13;16(10):1087-90.

PMID:
15973153
20.

A positron emission tomography (PET) study of cerebral dopamine D2 and serotonine 5-HT2A receptor occupancy in patients treated with cyamemazine (Tercian).

Hodé Y, Reimold M, Demazières A, Reischl G, Bayle F, Nuss P, Hameg A, Dib M, Macher JP.

Psychopharmacology (Berl). 2005 Jul;180(2):377-84. Epub 2005 Mar 15.

PMID:
15948013
21.

Reduction of extracellular dopamine and metabolite concentrations in rat striatum by low doses of acute cyamemazine.

Peinado J, Hameg A, Garay RP, Bayle F, Nuss P, Dib M.

Naunyn Schmiedebergs Arch Pharmacol. 2003 Feb;367(2):134-9. Epub 2003 Jan 23.

PMID:
12595954
22.

Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes.

Hameg A, Bayle F, Nuss P, Dupuis P, Garay RP, Dib M.

Biochem Pharmacol. 2003 Feb 1;65(3):435-40.

PMID:
12527336
23.

5-HT2A receptor antagonist properties of cyamemazine in rat and guinea pig smooth muscle.

Alvarez-Guerra M, Hameg A, Bayle F, Dib M, Garay RP.

Eur J Pharmacol. 2002 Nov 15;454(2-3):235-9.

PMID:
12421652
24.

Riluzole rescues cochlear sensory cells from acoustic trauma in the guinea-pig.

Wang J, Dib M, Lenoir M, Vago P, Eybalin M, Hameg A, Pujol R, Puel JL.

Neuroscience. 2002;111(3):635-48.

PMID:
12031350
25.

Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes.

Sharif S, Arreaza GA, Zucker P, Mi QS, Sondhi J, Naidenko OV, Kronenberg M, Koezuka Y, Delovitch TL, Gombert JM, Leite-De-Moraes M, Gouarin C, Zhu R, Hameg A, Nakayama T, Taniguchi M, Lepault F, Lehuen A, Bach JF, Herbelin A.

Nat Med. 2001 Sep;7(9):1057-62.

PMID:
11533711
26.

IL-18 enhances IL-4 production by ligand-activated NKT lymphocytes: a pro-Th2 effect of IL-18 exerted through NKT cells.

Leite-De-Moraes MC, Hameg A, Pacilio M, Koezuka Y, Taniguchi M, Van Kaer L, Schneider E, Dy M, Herbelin A.

J Immunol. 2001 Jan 15;166(2):945-51.

27.

NKT lymphocyte ontogeny and function are impaired in low antibody-producer Biozzi mice: gene mapping in the interval-specific congenic strains raised for immunomodulatory genes.

Araujo LM, Puel A, Gouarin C, Hameg A, Mevel JC, Koezuka Y, Bach JF, Mouton D, Herbelin A.

Int Immunol. 2000 Nov;12(11):1613-22.

PMID:
11058581
28.

A subset of NKT cells that lacks the NK1.1 marker, expresses CD1d molecules, and autopresents the alpha-galactosylceramide antigen.

Hameg A, Apostolou I, Leite-De-Moraes M, Gombert JM, Garcia C, Koezuka Y, Bach JF, Herbelin A.

J Immunol. 2000 Nov 1;165(9):4917-26.

29.

A distinct IL-18-induced pathway to fully activate NK T lymphocytes independently from TCR engagement.

Leite-De-Moraes MC, Hameg A, Arnould A, Machavoine F, Koezuka Y, Schneider E, Herbelin A, Dy M.

J Immunol. 1999 Dec 1;163(11):5871-6.

30.

IL-7 up-regulates IL-4 production by splenic NK1.1+ and NK1.1- MHC class I-like/CD1-dependent CD4+ T cells.

Hameg A, Gouarin C, Gombert JM, Hong S, Van Kaer L, Bach JF, Herbelin A.

J Immunol. 1999 Jun 15;162(12):7067-74.

31.

IL-7 reverses NK1+ T cell-defective IL-4 production in the non-obese diabetic mouse.

Gombert JM, Tancrède-Bohin E, Hameg A, Leite-de-Moraes MC, Vicari A, Bach JF, Herbelin A.

Int Immunol. 1996 Nov;8(11):1751-8.

PMID:
8943570

Supplemental Content

Support Center